{"DataElement":{"publicId":"62683","version":"3","preferredName":"Prior Chemotherapy Intravesical Treatment Type","preferredDefinition":"a description of one or more chemical agents or compounds used in the past to treat cancer of the bladder in an individual using implanted devices to deliver treatment to the targeted tumor.","longName":"PRIOR_CT_INVSC_TX_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2190114","version":"1","preferredName":"Prior Chemotherapy Intravesical Treatment","preferredDefinition":"information related to prior intravesical chemotherapy treatment.","longName":"PRIOR_CT_INVSC_TX","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206391","version":"1","preferredName":"Prior Chemotherapy","preferredDefinition":"Earlier in time or order.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","longName":"C25629:C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F3A3-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207391","version":"1","preferredName":"intravesical Therapy","preferredDefinition":"Within the bladder.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C13415:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravesical","conceptCode":"C13415","definition":"Within the bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-2252-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6CCC370-01E1-4806-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2015390","version":"3","preferredName":"Prior Chemotherapy Intravesical Treatment Type","preferredDefinition":"a description of one or more chemical agents or compounds used in the past to treat cancer of the bladder in an individual using implanted devices to deliver treatment to the targeted tumor.","longName":"PRIOR_CT_INVSC_TX_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"MMC","valueDescription":"MMC","ValueMeaning":{"publicId":"2559262","version":"1","preferredName":"MMC","longName":"2559262","preferredDefinition":"MMC","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B48B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"17F13379-CF37-5276-E044-0003BA3F9857","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-06","modifiedBy":"ONEDATA","dateModified":"2006-07-06","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"17F13379-CF41-5276-E044-0003BA3F9857","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-06","modifiedBy":"ONEDATA","dateModified":"2006-07-06","deletedIndicator":"No"},{"value":"Thiotepa","valueDescription":"THIOTEPA","ValueMeaning":{"publicId":"2560273","version":"1","preferredName":"THIOTEPA","longName":"2560273","preferredDefinition":"THIOTEPA","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thiotepa","conceptCode":"C875","definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B87E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"17F13379-CF4B-5276-E044-0003BA3F9857","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-06","modifiedBy":"ONEDATA","dateModified":"2006-07-06","deletedIndicator":"No"},{"value":"Gemcitabine","valueDescription":"Gemcitabine","ValueMeaning":{"publicId":"5242658","version":"1","preferredName":"Gemcitabine","longName":"5242658","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-98BB-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F657E6-2F7E-15B3-E053-F662850A1D10","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"BCG","valueDescription":"BCG Vaccine","ValueMeaning":{"publicId":"5654664","version":"1","preferredName":"BCG Vaccine","longName":"5654664","preferredDefinition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCG Vaccine","conceptCode":"C298","definition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E22FDA-53D4-0E13-E053-F662850AD9C8","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F657E6-2F88-15B3-E053-F662850A1D10","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTEP CDE Committee","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17F13379-CF23-5276-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-06","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-06","modifiedBy":"HARTLEYG","dateModified":"2019-10-02","changeDescription":"updated for ISO compliance","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811907","version":"1","longName":"Bladder","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000311","version":"1","longName":"Met/Urothelial","context":"CTEP"},{"publicId":"10000462","version":"1","longName":"Muscle Invasive Blad","context":"CTEP"},{"publicId":"10000312","version":"1","longName":"Superficial Bladder","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Type of Prior Chemotherapy","type":"Preferred Question Text","description":"Type of Prior Chemotherapy","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Prior Intravesical Chemotherapy Type","url":null,"context":"CTEP"}],"origin":"CTEP CDE Committee","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"17F11CB1-C069-537E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-06","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-06","modifiedBy":"REEVESD","dateModified":"2011-04-05","changeDescription":"updated for ISO compliance","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}